Download PDF
Digestive Disease Interventions 2023; 07(02): 128-137
DOI: 10.1055/s-0043-1761632
Review Article

Complications of Transcatheter Arterial Chemoembolization for Treatment of Primary Liver Cancer

Paula M. Novelli 
1   Division of Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
,
Christopher Gustafson
2   Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
,
Philip D. Orons
1   Division of Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Transcatheter arterial chemoembolization (TACE) is the standard practice in treating both primary and metastatic liver neoplasms. TACE is a practical, minimally invasive procedure involving the delivery of chemotherapeutic agents into the artery supplying a tumor while simultaneously embolizing its blood supply. This approach can be used for curative and palliative intent across multiple cancer types. Historically, TACE has been instrumental in the treatment algorithms for hepatocellular carcinoma, allowing patients with unresectable disease to be downstaged and to slow disease progression, affording opportunities for transplantation and increased survival. Although benefits of TACE include lower morbidity and mortality versus systemic chemotherapy and surgical approaches, the procedure has risks and complications. Interventional radiologists and physicians involved in the care of these patients should be aware of the associated complications including avoidance and treatment strategies.

Keywords

hepatocellular carcinoma - transarterial chemoembolization - transcatheter locoregional therapy - complications


Publication History

Received: 01 December 2022

Accepted: 22 December 2022

Article published online:
13 February 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022; 76 (03) 681-693
    CrossrefPubMedGoogle Scholar
  • 2 Lucatelli P, Guiu B. 2022 update of BCLC treatment algorithm of HCC: What's new for interventional radiologists?. Cardiovasc Intervent Radiol 2022; 45 (03) 275-276
    CrossrefPubMedGoogle Scholar
  • 3 Clark TW. Complications of hepatic chemoembolization. Semin Intervent Radiol 2006; 23 (02) 119-125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Gayed A, Yamada R, Bhatia S. et al. SIR quality improvement standards on radial access. J Vasc Interv Radiol 2021; 32: 761 e21
    CrossrefPubMedGoogle Scholar
  • 5 Hsin IF, Hsu CY, Huang HC. et al. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol 2011; 45 (06) 556-562
    CrossrefPubMedGoogle Scholar
  • 6 Raoul JL, Sangro B, Forner A. et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (03) 212-220
    CrossrefPubMedGoogle Scholar
  • 7 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (02) 164-173
    CrossrefPubMedGoogle Scholar
  • 8 Silva JP, Berger NG, Tsai S. et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford) 2017; 19 (08) 659-666
    CrossrefPubMedGoogle Scholar
  • 9 Yoon HJ, Kim JH, Kim KA. et al. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clin Radiol 2010; 65 (04) 271-277
    CrossrefPubMedGoogle Scholar
  • 10 Gaba RC, Lokken RP, Hickey RM. et al; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol 2017; 28 (09) 1210-1223.e3
    CrossrefPubMedGoogle Scholar
  • 11 Song SY, Chung JW, Han JK. et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12 (03) 313-320
    CrossrefPubMedGoogle Scholar
  • 12 de Baère T, Roche A, Amenabar JM. et al. Liver abscess formation after local treatment of liver tumors. Hepatology 1996; 23 (06) 1436-1440
    CrossrefPubMedGoogle Scholar
  • 13 Woo S, Chung JW, Hur S. et al. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol 2013; 200 (06) 1370-1377
    CrossrefPubMedGoogle Scholar
  • 14 Toro A, Bertino G, Arcerito MC. et al. A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Case Rep Surg 2015; 2015: 873601
    PubMedGoogle Scholar
  • 15 Schwab D, Grauer M, Hahn EG, Mühldorfer S. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment Pharmacol Ther 2005; 22 (05) 417-422
    CrossrefPubMedGoogle Scholar
  • 16 Dhamija E, Paul SB, Gamanagatti SR, Acharya SK. Biliary complications of arterial chemoembolization of hepatocellular carcinoma. Diagn Interv Imaging 2015; 96 (11) 1169-1175
    CrossrefPubMedGoogle Scholar
  • 17 Poggi G, Pozzi E, Riccardi A. et al. Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver. Anticancer Res 2010; 30 (12) 5159-5164
    PubMedGoogle Scholar
  • 18 Yu JS, Kim KW, Jeong MG, Lee DH, Park MS, Yoon SW. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 2002; 25 (04) 270-274
    CrossrefPubMedGoogle Scholar
  • 19 Wagnetz U, Jaskolka J, Yang P, Jhaveri KS. Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome. J Comput Assist Tomogr 2010; 34 (03) 348-353
    CrossrefPubMedGoogle Scholar
  • 20 Kang B, Kim HC, Chung JW, Hur S, Jae HJ, Park JH. The origin of the cystic artery supplying hepatocellular carcinoma on digital subtraction angiography in 311 patients. Cardiovasc Intervent Radiol 2014; 37 (05) 1268-1282
    CrossrefPubMedGoogle Scholar
  • 21 Miyayama S, Matsui O, Nishida H. et al. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma fed by the cystic artery. J Vasc Interv Radiol 2003; 14 (9, Pt 1): 1155-1161
    CrossrefPubMedGoogle Scholar
  • 22 Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 2005; 25 (Suppl. 01) S25-S39
    CrossrefPubMedGoogle Scholar
  • 23 Lee AJ, Gomes AS, Liu DM, Kee ST, Loh CT, McWilliams JP. The road less traveled: importance of the lesser branches of the celiac axis in liver embolotherapy. Radiographics 2012; 32 (04) 1121-1132
    CrossrefPubMedGoogle Scholar
  • 24 Shiozawa K, Watanabe M, Ikehara T. et al. Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Case Rep Oncol 2014; 7 (03) 739-745
    CrossrefPubMedGoogle Scholar
  • 25 Reis SP, Yokoo T, Trimmer CK. Hemorrhage following drug-eluting bead transarterial chemoembolization of hepatocellular carcinoma. J Am Osteopath Coll Radiol 2014; 3 (03) 21-24
    PubMedGoogle Scholar
  • 26 Monsignore LM, Elias-Junior J, Muglia VF. et al. Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma. Clinics (São Paulo) 2015; 70 (12) 781-789
    CrossrefPubMedGoogle Scholar
  • 27 Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. Eur Radiol 2009; 19 (08) 2016-2023
    CrossrefPubMedGoogle Scholar
  • 28 Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 1997; 52 (01) 36-40
    CrossrefPubMedGoogle Scholar
  • 29 Nhu QM, Knowles H, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol 2016; 6 (03) 69-75
    CrossrefPubMedGoogle Scholar
  • 30 Xu H, Yang R, Wang X, Zhu X, Chen H. Symptomatic pulmonary lipiodol embolism after transarterial chemoembolization for hepatic malignant tumor: clinical presentation and chest imaging findings. Chin Med J (Engl) 2014; 127 (04) 675-679
    PubMedGoogle Scholar
  • 31 Tajima T, Honda H, Kuroiwa T. et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol 2002; 13 (9, Pt 1): 893-900
    CrossrefPubMedGoogle Scholar
  • 32 Liou TC, Shih SC, Kao CR, Chou SY, Lin SC, Wang HY. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol 1995; 23 (05) 563-568
    CrossrefPubMedGoogle Scholar
  • 33 Kessler JM, Harini A, Hong K, Georgiades CS, Geschwind JF. Toxicity of transcatheter arterial chemoembolization for unresectable liver tumors. J Vasc Interv Radiol 2005; 16: S54
    PubMedGoogle Scholar
  • 34 Buijs M, Vossen JA, Frangakis C. et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization – single-center experience. Radiology 2008; 249 (01) 346-354
    CrossrefPubMedGoogle Scholar
  • 35 Khalaf MH, Sundaram V, AbdelRazek Mohammed MA. et al. A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma. Radiology 2019; 290 (01) 254-261
    CrossrefPubMedGoogle Scholar